Navigation Links
ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
Date:2/13/2008

- Data on ARIUS' novel CD9 therapeutic antibody to be presented at AACR

Special Conference on Cancer Stem Cells -

TORONTO, Feb. 13 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that new information on the preclinical activity of its anti-CD9 cancer stem cell antibody will be presented at the AACR Special Conference on Cancer Stem Cells entitled "The Role of Cancer Stem Cells in the Initiation and Propagation of Tumorigenesis," held on February 12th-15th in Los Angeles. The Company will disclose data demonstrating that its CD9 antibody not only targets leukemia cancer stem cells, but also leads to a dramatic reduction in their capacity to self-renew or give rise to further leukemia. These findings were discovered in collaboration with John E. Dick, PhD, the Canada Research Chair in Stem Cell Biology with the University Health Network in Toronto, Canada.

The poster presentation (Wednesday, February 13th 2008, from 4:30-6:30 pm) will outline the activity of ARIUS' anti-CD9 antibody, AR40A746.2.3, against acute myeloid leukemia (AML). The long-term survival expectation for patients with AML is poor due to disease relapse and resistance to chemotherapy. CD9 appears to be an important driver for leukemia and potentially other cancer stem cells, which often survive treatment, continue to multiply and go on to seed new tumors. Studies of patients with different types of cancer have demonstrated that the presence of CD9 can be linked to lower survival rates. AR40A746.2.3 has previously been found to control tumor growth and improve survival in pre-clinical breast and pancreatic cancer models.

"Since some cancer stem cells have been shown to be highly resistant to traditional cancer therapies and are believed to contribute to treatment resistance, the selectivity of ARIUS' anti-CD9 antibody for leukemic cancer stem
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
2. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
3. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
4. ARIUS to present at Chinese Global Financial Forum
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
8. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
9. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 ... technologies such as the Bioruptor® and complete solutions ... system for chromatin immunoprecipitation, alleviating the need for ... and controls needed for ChIP of histones or ...
(Date:1/22/2015)... PALO ALTO, Calif. , Jan. 22. 2015  Varian Medical ... equipment and software, has been honored for its commitment to ... most sustainable companies. Varian is the highest ranked healthcare equipment ... ranking, announced today during the World Economic Forum at ...
(Date:12/25/2014)... December 25, 2014 The report “Service ... Product Type & Provider Type - Global Advancements, Worldwide ... with an in-depth analysis and forecasting of revenues. ... through 221 pages and in-depth TOC on “Service Quality ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Varian Honored Among World's 100 Most Sustainable Corporations 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... A/S Summons Annual General Meeting Summary: Genmab ... COPENHAGEN, Denmark, April 7 Genmab A/S (OMX:,GEN) summon the ... CEST at the Radisson SAS Scandinavia Hotel, Amager Boulevard 70, ... Board of Directors on the Company,s activities during,the year., ...
... contains two different types of components: magnetic components, which ... operations. A University of Missouri researcher, as part of ... two functions in a single hybrid material. This new ... functions and is expected to permit the design of ...
... Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... today that the first New Zealand patient,was treated ... in December 2007. A second patient was treated ... first drug-eluting stent for peripheral,arterial disease (PAD) and ...
Cached Biology Technology:Genmab A/S - Notice to Convene Annual General Meeting 2Genmab A/S - Notice to Convene Annual General Meeting 3Genmab A/S - Notice to Convene Annual General Meeting 4Genmab A/S - Notice to Convene Annual General Meeting 5Genmab A/S - Notice to Convene Annual General Meeting 6Genmab A/S - Notice to Convene Annual General Meeting 7Hybrid computer materials may lead to faster, cheaper technology 2Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 2Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 3Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 4
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... Apollo Robbins for the 2015 International CES debut of ... Robbins will be at the NXT-ID booth January 6th ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... The North American perimeter security market is ... to 2019. Although the U.S. market holds a larger share ...
(Date:12/17/2014)... 15, 2014 The Defense Logistics Agency is insourcing ... prevent counterfeit microcircuits from entering into its supply chain. ... microcircuit anti-counterfeit initiative dubbed DNA marking. The capability will ... reliability throughout the supply chain. The new quality control ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... Leicester and University of California Los Angeles (UCLA) have ... in the body. They have filed two patents ... catalyst for lowering levels of ,bad, cholesterol. Two ... of the regulation of low-density lipoprotein (LDL) or "bad" ...
... have created a scientifically rigorous analogy that shows the similarities ... structure of a melody, proving that the structure of each ... The step-by-step comparison begins with the primary building blocks ... wave and moves up to the level of a ...
... magnetic resonance imaging measures were associated with prognostic ... imaging for prediction of disease prognosis and stratification ... data presented at the 2011 CTRC-AACR San Antonio ... "Breast cancers are heterogeneous, and different subtypes of ...
Cached Biology News:New advance announced in reducing 'bad' cholesterol 2Researchers link patterns seen in spider silk, melodies 2Researchers link patterns seen in spider silk, melodies 3MRI may be noninvasive method to measure breast cancer prognosis 2
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
Mouse Anti-Amyloid beta [1-16], clone 6E10, Monoclonal Antibody...
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
E1A (adenovirus early region 1)...
Biology Products: